Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033592 · ClinicalTrials.gov registry record · Phase 3
Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking
A Phase 3 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,708
- Enrollment target
- 20
- Study locations
NCT00033592 is a Phase 3 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 1,708 participants, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00033592, a Phase 3 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,708 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop smoking and prevent them from starting smoking again. It is not yet known whether a nicotine inhaler or bupropion are more effective alone or combined for stopping smoking. PURPOSE: Randomized phase III trial to compare the effectiveness of the nicotine inhaler or bupropion alone to that of the nicotine inhaler combined with bupropion in helping people to stop smoking and prevent starting smoking again.
Conditions Studied
Interventions
- OTHER placebo
- DRUG bupropion hydrochloride
- DRUG nicotine
Study Locations (20)
Minnesota
- CCOP - Duluth - Duluth
- Mayo Clinic Cancer Center - Rochester
- CentraCare Clinic - Saint Cloud
- CCOP - Metro-Minnesota - Saint Louis Park
Iowa
- CCOP - Cedar Rapids Oncology Project - Cedar Rapids
- CCOP - Iowa Oncology Research Association - Des Moines
- Siouxland Hematology-Oncology - Sioux City
North Dakota
- Medcenter One Health System - Bismarck
- CCOP - Merit Care Hospital - Fargo
- Altru Health Systems - Grand Forks
Illinois
- CCOP - Illinois Oncology Research Association - Peoria
- CCOP - Carle Cancer Center - Urbana
Kansas
- CCOP - Wichita - Wichita
- Cancer Center of Kansas - Wichita - Wichita
Arizona
- CCOP - Scottsdale Oncology Program - Scottsdale
District of Columbia
- MBCCOP-Howard University Cancer Center - Washington D.C.
Louisiana
- CCOP - Ochsner - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,708 participants |
| Start Date | 2002-02 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033592
The ClinicalTrials.gov registry entry for NCT00033592 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,708 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00033592 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Minnesota, Iowa, North Dakota.
Frequently Asked Questions
What is clinical trial NCT00033592 about?
NCT00033592 is a clinical study titled "Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking". RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop smoking and prevent them from starting smoking again. It is not yet known whether a nicotine inhaler or bupropion are more effective alone or combined for stopping smoking. PURPOSE: Randomized phase III tr...
What is the current status of trial NCT00033592?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,708 participants. The study started on 2002-02. Estimated completion is 2006-07.
What conditions does trial NCT00033592 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00033592?
The interventions under investigation include: placebo (OTHER), bupropion hydrochloride (DRUG), nicotine (DRUG).
Who is sponsoring clinical trial NCT00033592?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00033592 being conducted?
This trial has 20 study locations across Arizona, District of Columbia, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.